LGI1 and viral encephalitis: During the follow-up period, 33 (17.84%) patients experienced a relapse, 19 with anti-NMDAR encephalitis, 7 with anti-LGI1 encephalitis, 3 with anti-CASPR2 encephalitis, 3 with anti-GABABR encephalitis, and 1 with anti-AMPAR encephalitis.